With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

A recent breakthrough in medical research offers exciting possibilities for people dealing with diabetes and obesity. This ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th ...

Popflex gets a Target boost and Golden Globes give stage to weight loss drugs—plus, why it was a bad week for H&R Block, REI ...